Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

AMRX stock hub

Amneal Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AMRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

4.2B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AMRX

In the news

Latest news · AMRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E12.2

P25 12.3P50 18.4P75 33.1

Trailing P/E35.6

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC18.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AMRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

242

Groups with data

Currency

USD

Showing 242 of 242 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001723128
Company name	Amneal Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	03168L105
Employees	8,700
Employees Change	400%
Employees Change Percent	4.82
Enterprise value	$6.7B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Isin	US03168L1052
Last refreshed	2026-05-10
Market cap	$4.2B
Market cap category	Mid-Cap
Price	$13.2
Price currency	USD
Rev Per Employee	350,098.74x
Sector	Healthcare
Sic	2834
Symbol	AMRX
Website	https://www.amneal.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.9%
EV Earnings	54.92x
EV Sales Forward	2.09x
EV/EBIT	14.54x
EV/EBITDA	10.04x
EV/FCF	32.36x
EV/Sales	2.2x
FCF yield	4.92%
Forward P/E	12.24x
P/B ratio	105.43x
P/E ratio	35.57x
P/S ratio	1.38x
PS Forward	1.31x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	15.14%
EBITDA Margin	21.92%
FCF margin	6.8%
Gross margin	39.16%
Gross Profit	$1.2B
Gross Profit Growth	15.53%
Gross Profit Growth Q	25.36%
Gross Profit Growth3 Y	14%
Gross Profit Growth5 Y	12.68%
Net Income	$122.1M
Net Income Growth Q	410.5%
Net Income Growth Quarters	6%
Net Income Growth Years	1%
Pretax Margin	5.97%
Profit Margin	4.01%
Profit Per Employee	$14,037
Profitable Years	1
ROA	8.35
Roa5y	4.94
ROCE	16.4
ROIC	18.6
Roic5y	9.95

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	82.9%
Cagr3y	90.12%
Cagr5y	20.48%
EPS Growth Q	384.6
EPS Growth Quarters	2
EPS Growth Years	3
FCF Growth	-14.54%
FCF Growth3 Y	77.67%
FCF Growth5 Y	-12.79%
OCF Growth	-0.35%
OCF Growth3 Y	53.56%
OCF Growth5 Y	-8.55%
Revenue Growth	7.62x
Revenue Growth Q	3.9x
Revenue Growth Quarters	20x
Revenue Growth Years	6x
Revenue Growth3 Y	10.26x
Revenue Growth5 Y	8.92x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.88
Assets	$3.5B
Cash	$200.6M
Current Assets	$1.8B
Current Liabilities	$728M
Debt	$2.7B
Debt EBITDA	$3.92
Debt Equity	$67.51
Debt FCF	$13.01
Equity	$39.9M
Interest Coverage	1.94
Liabilities	$3.5B
Long Term Assets	$1.7B
Long Term Liabilities	$2.8B
Net Cash	$-2.5B
Net Cash By Market Cap	$-59.27
Net Debt EBITDA	$3.74
Net Debt Equity	$62.49
Net Debt FCF	$12.04
Tangible Book Value	$-1.2B
Tangible Book Value Per Share	$-3.68
WACC	10.45

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.47
Inventory Turnover	2.98
Net Working Capital	$890.7M
Quick ratio	1.52
Working Capital	$1.1B
Working Capital Turnover	$4.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5.2%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	82.83%
200-day SMA	11.72
3Y total return	587.5%
50-day SMA	12.77
50-day SMA vs 200-day SMA	50over200
5Y total return	153.85%
All Time High	24.48
All Time High Change	-46.08%
All Time High Date	2018-08-22
All Time Low	1.24
All Time Low Change	964.52%
All Time Low Date	2023-03-28
ATR	0.47
Beta	1.32
Beta1y	1.21
Beta2y	0.87
Ch YTD	4.76
High	13.81
High52	15.42
High52 Date	2026-02-17
High52ch	-14.4%
Low	13.12
Low52	7.02
Low52 Date	2025-05-23
Low52ch	88.03%
Ma50ch	3.38%
Premarket Change Percent	0.22
Premarket Price	$13.75
Premarket Volume	990
Price vs 200-day SMA	12.68%
RSI	53.46
RSI Monthly	71.21
RSI Weekly	55.79
Sharpe ratio	1.96x
Sortino ratio	3.32
Total Return	-5.2%
Tr YTD	4.76
Tr1m	7.14%
Tr1w	2.88%
Tr3m	-9.09%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	2
Analyst Price Target Top	$16
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.17
Earnings EPS Estimate Growth	-19.05
Earnings Revenue Estimate	715,378,816x
Earnings Revenue Estimate Growth	2.87x
Operating Income	$461.2M
Operating Income Growth	26.63
Operating Income Growth Q	40.11
Operating Income Growth3 Y	26.9
Operating Income Growth5 Y	29.75
Operating margin	15.14
Price target	$15.6
Price Target Change	$18.18
Price Target Change Top	$21.21

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	178,455,906%
Float Percent	55.94%
Net Borrowing	119,478,000
Shares Insiders	44.06%
Shares Institutions	53.06%
Shares Out	319,022,792
Shares Qo Q	0.26%
Shares Yo Y	5.2%
Short Float	4.79%
Short Ratio	4.74
Short Shares	2.68

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$173.7M
Average Volume	1,604,541.95x
Bv Per Share	-0.14
CAPEX	$-98.6M
Ch1m	7.14
Ch1w	2.88
Ch1y	82.83
Ch3m	-9.09
Ch3y	587.5
Ch5y	153.8
Ch6m	16.1
Change	-3.79%
Change From Open	-3.08
Close	13.72
Days Gap	-0.73
Depreciation Amortization	206,604,000
Dollar Volume	20,062,046.4
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$461.2M
EBITDA	$667.8M
EPS	$0.37
F Score	7
FCF	$207.3M
FCF EV Yield	3.09x
FCF Per Share	$0.65
Financing CF	-51,419,000
Fiscal Year End	December
Founded	2,002
Goodwill	593,800,000
Income Tax	$584,000
Investing CF	-116,175,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-27
Ma150	12.53
Ma150ch	5.35%
Ma20	13.06
Ma20ch	1.1%
Net CF	136,014,000
Next Earnings Date	2026-08-04
Open	13.62
Optionable	Yes
P FCF Ratio	20.32
P OCF Ratio	13.77
Position In Range	11.59
Post Close	13.2
Postmarket Change Percent	1.21
Postmarket Price	$13.36
Ppne	558,762,000
Pre Close	13.72
Price Date	2026-05-08
Price EBITDA	$6.31
Relative Volume	0.95x
Revenue	3,045,859,000x
SBC By Revenue	1.1x
Share Based Comp	33,511,000
Tax By Revenue	0.02x
Tax Rate	0.32%
Tr6m	16.1%
Us State	New Jersey
Volume	1,519,852
Z Score	2.02

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AMRX pay a dividend?

Capital-return profile for this ticker.

Performance

AMRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AMRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+53.1%

Float: +55.9% of shares outstanding

Insider ownership

+44.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AMRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.5

Neutral momentum band

Price vs 200-day MA

+12.7%

50/200-day relationship not available

Beta (5Y)

1.32

More volatile than the market

Sharpe ratio

1.96

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AMRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AMRX stock rating?

Amneal Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AMRX analysis?

The full report lives at /stocks/AMRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AMRX?

The latest report frames AMRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AMRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.